Sanofi is Strengthening its Position in the Production of Insulin in Russia

| By | insulin, Sanofi
0
247

Sanofi summed up the results of 2019 and reported the results of production of innovative medicines for the treatment of diabetes at the plant Sanofi Aventis Vostok in the Orlov region.

“2019 is a successful and productive year for Sanofi-Aventis East. We launched a full pharmaceutical production cycle within the shortest time [except the production of a pharmaceutical substance – Ed.] of Toujeo SoloStar®, the latest generation of basal insulin. We started production of Soliqua SoloStar®, an innovative drug for the treatment of type 2 diabetes. In 2020, Sanofi Aventis Vostok will celebrate its 10th anniversary. We are not resting on our laurels and plan to invest in the development of our production in Russia in the future to make innovative products widely available to Russian patients,” said Frederic Jumel, Business Unit Head – Diabetes and Praluent® at Sanofi.

In 2019, the Sanofi Aventis Vostok plant produced more than 8 million Toujeo SoloStar® insulin pens, the latest generation of basal insulin for the treatment of diabetes types 1 and 2. The drug product was registered in the USA and EU in 2015 and in May 2016 in Russia.

In 2019, more than 100 thousand insulin pens of the innovative preparation Soliqua SoloStar®, registered in Russia in 2018, were produced. The drug is indicated for use in the treatment of adult patients with type 2 diabetes and allows more than 70% of patients to achieve glycemic goals. The Sanofi Aventis Vostok plant is the second Sanofi plant in the world to assemble and package injection pens and produce Soliqua SoloStar®.

VIARUSSIAN VERSION
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.